Posts Archive

NCT03544281: Phase 2: To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in...

DREAMM 2 Relapsed & Refractory Multiple Myeloma A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants...

NCT03424603: Phase 1: Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies Study of...

COLUMBA study A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory...

CRB-402 Study of bb21217 in Multiple Myeloma Relapsed Refractory Multiple Myeloma RRMM Study CRB-402 is a 2-part, non-randomized, open...

The APOLLO study EMN14/54767414MMY3013 Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed...

Phase 3 CANDOR study Dara-Kd Kd Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple...

NCT03031730: Phase 1: Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma Testing the Addition...

OCEAN NCT03151811: Phase 3: A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to...

ASCENT TRIAL Dara-KRd Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant (ASCENT) This study evaluates the...

IMROZ Study NCT03319667 Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not...

NCT03374085: Phase 1/2: CC-92480 Monotherapy and with Dex in Relapsed / Refractory Multiple Myeloma A Safety, PK and Efficacy Study of...

GMMG - The German Speaking Myeloma Multicenter Group GMMG-CONCEPT trial Isa-KRd NCT03104842: Phase 2 - Evaluation iNduction,...

NCT03275103: Phase 1 - Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) A Phase...

MajesTEC1 Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory...

NCT03218683: Phase 1/2: Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies....

IKEMA Isa-Kd Vs Kd Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In...

NCT03269136 MAGNETISMM-1 RRMM NCT03269136: Phase 1 -PF-06863135 As Single Agent & with Immunomodulatory Agents In relapsed Myeloma To...

A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed...